Apollo Hospitals Enterprise Limited has informed the Exchange regarding Outcome of Board Meeting held on August 12, 2025.
APOLLOHOSP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Apollo Hospitals reported strong Q1 FY26 results with consolidated revenue rising 15% year-on-year to Rs. 5,842 crore, EBITDA up 26% to Rs. 852 crore, and profit after tax growing 42% to Rs. 433 crore. All three core segments contributed — Healthcare Services revenue grew 11% to Rs. 2,935 crore, Digital Health & Pharmacy distribution grew 19% to Rs. 2,472 crore, and Retail Health & Diagnostics grew 19% to Rs. 435 crore. The Board approved acquiring the remaining 50% stake in Apollo Gleneagles PET-CT Private Limited (AGPCL) from Parkway Healthcare for Rs. 85 million, making it a wholly owned subsidiary expected by end-August 2025. The Board also granted 327,494 stock options at Rs. 5,258 per share under the ESOP 2024 plan. Additionally, the composite scheme to demerge the omnichannel pharmacy and digital health business into a new listed entity, Apollo Healthtech Limited, has been filed with stock exchanges for approval. Expansion plans to add over 4,300 beds over five years with investments of around Rs. 7,600 crore were reiterated.
Strong quarterly performance with broad-based growth across all segments is positive for shareholders. The AGPCL acquisition consolidates diagnostic services under full control, while the demerger of the pharmacy and digital health business could unlock separate value for shareholders once the new entity lists. Investors should watch for NCLT and other regulatory approvals on the demerger scheme.